Mechanisms of resistance to serpatinib

Selpatinib is a targeted therapy drug targeting RET gene fusions or mutations. It has shown significant efficacy in the fight against cancers such as non-small cell lung cancer and thyroid cancer. However, like other targeted drugs, drug resistance may also occur during treatment with seputinib, and its resistance mechanisms are complex and diverse.

The resistance mechanism of seputinib may first be related to the bypass activation ofMAPK pathway. Under long-term drug treatment, cancer cells may develop new signaling pathways that bypass the RET kinase inhibited by seputinib and continue to drive tumor growth. In addition, secondary RET mutations are also an important cause of drug resistance. These mutations may change the structure of the RET kinase so that seputinib can no longer bind to it effectively, thereby reducing the drug's efficacy.

In addition to the above mechanisms, MET amplification is also considered to be a key factor in seprotinib resistance. In some cases, the MET gene is amplified in cancer cells, leading to overexpression of MET protein. This amplification may provide cancer cells with a new survival and proliferation pathway that allows them to continue to survive and grow under treatment with seputinib. For this situation, the combined use of MET inhibitors such as capmatinib may be an effective strategy to overcome drug resistance.

It is worth noting that the resistance mechanism of seputinib may vary depending on individual differences, tumor type and disease stage. Therefore, for patients with drug resistance, comprehensive molecular testing is needed to understand the specific resistance mechanisms and develop personalized treatment plans accordingly.

Overall, although seputinib is a highly effective targeted therapy, the emergence of drug resistance may limit its long-term efficacy. In-depth study of the resistance mechanism of seputinib and exploration of effective response strategies are of great significance for improving the treatment effect and quality of life of patients.